Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 439-270-3 | CAS number: 260408-02-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Key value for chemical safety assessment
- Bioaccumulation potential:
- low bioaccumulation potential
Additional information
The acute oral and dermal toxicity tests with SPS-100 showed the LD50 being higher than 2000 mg/kg body weight in both
cases. The 28-day subacute toxicity test and the reproduction/
developmental toxicity screening test for 28-days revealed a
NOAEL of 1000 mg/kg/day in rat. Therefore, an extensive
toxicokinetic assessment is considered of limited value.
Below, a summary of the anticipated toxicokinetic behaviour of
SPS-100 is given.
The water solubility of SPS-100 is low (<4-44 µg/l), caused
by the presence of the strong apolar groups. Since in
general a compound needs to be dissolved before it can be
taken up from the gastro-intestinal tract, it is unlikely
that SPS-100 will show a high systemic exposure after oral
administration as a powder. However, in the presence of food
and bile salts, the solubility might be increased and thus
the systemic exposure might be higher. It is to be expected
that the oral bioavailability, and thus the systemic
exposure, of SPS-100 will be low (1).
In the gastro-intestinal tract, hardly any degradation of
the product is to be expected. In the case absorption of
SPS-100 occurs, the unsaturated rings will undergo extensive
hydroxylation, followed by rapid sulfation or
glucuronidation (2). The resulting metabolites will be
extensively excreted via bile and/or urine.
SPS-100 will show a high volume of distribution, because of
the high lipophilicity of the compound. It will be
extensively distributed into peripheral tissue, especially
fatty tissues. Accumulation in fatty tissues is therefore
anticipated. The plasma protein binding is expected to be
high.
Since it is generally accepted that substances with log Po/w
ranging from 0.1 to 6 penetrate the skin easily (3), it is
to be expected that the penetration of the skin by SPS-100
will be limited.
Based on the expected kinetic behaviour in the body, as
described above, SPS-100 will hardly be absorbed after oral
administration, because of its insolubility and the expected
metabolism in the gut. If absorption occurs, SPS-100 will
be extensively metabolised in the liver and rapidly excreted
via bile and/or urine. Therefore, accumulation in the body
during prolonged exposure will be very low, although some
retention in fatty tissues may occur.
References.
1. L.S. Schanker et al. Absorption of drugs from the
rat small intestine. J. Pharmacol. Exp. Ther. 123 (1958) pp
81-88.
2. A. Parkinson. In: Casarett and Doull's Toxicology,
The basic science of poisons, fifth edition. Eds. C.D.
Klaassen, M.O. Amdur and J. Doull. Chapter 6:
Biotransformation of xenobiotics. McGraw-Hill, New York
(1996).
3. T.G. Vermeire et al., Estimation of consumer
exposure to chemicals: application of simple models. The
Science of the Total Environment 136 (1993) 155-176.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
